This trial (n=61) assessed clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine infusions. Depressive symptoms were assessed using the MADRS. The number of treatment failures and the severity of illness were predictors of fewer remissions and responses to depressive symptoms.
Abstract
“Background: Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment-resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressants, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine infusions.
Methods: A randomized, double-blind, active-controlled, non-inferiority trial using ketamine and esketamine in TRD. Individuals diagnosed with MDD according to the Diagnostic and Statistical Manual of Mental Disorders version IV and fulfilling TRD criteria were recruited from March 2017 to June 2018. Participants received a single subanesthetic dose of ketamine (0.5 mg/kg) or esketamine (0.25 mg/kg) for 40 min. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and symptom remission was defined as a MADRS score ≤7 and response defined as ≥50% reduction in depressive symptom severity, 24 h and 7 days after the infusion. Clinical variables were selected based on previous clinical trials. Stepwise backward logistic regression was used, considering a confidence level of 95%.
Results: 61 subjects were included: 39 (63.9%) were females with a mean age of 47.2 ± 14.9. Higher number of therapeutic failures (Odds Ratio (OR) = 0.677; 95% confidence interval (CI): 0.47–0.97) and higher severity of illness (OR = 0.912; 95% CI: 0.83–0.99) were associated with fewer remissions of depressive symptoms 7 days after intervention, and with fewer response in 24 h (OR = 0.583; 95% CI: 0,40; 0,84 and OR = 0.909; 95% CI: 0,83; 0,99, respectively).
Conclusion: The number of treatment failures and severity of illness were predictors of fewer remissions and responses of depressive symptoms in this TRD population. The study of predictors of remission may contribute to a better selection of patients that may benefit from receiving ketamine.”
Authors: Ana P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo, Flaiva Vieira, Rodrigo P. Mello, Ana T. Caliman-Fontes, Mariana V. Echegaray, Roberta F. Marback, Livia N. F. Guerreiro-Cost, Breno Souza-Marques, Cassio Santos-Lima, Lucca S. Souza, Igor D. Bandeira, Falvio Kapczinski, Acioly L. T. Lacerda & Lucas C. Quarantini
Summary of Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression
Introduction
Major Depressive Disorder (MDD) is a mental disorder that affects 300 million people worldwide. The racemic ketamine, an NmethylDaspartate receptorantagonist, has shown a promising rapid antidepressant effect for treatment resistant depression.
Current studies indicate that there is no single clinical characteristic that determines if a TRD patient is going to achieve remission or response to ketamine therapy. However, some clinical variables such as severity of illness, anxiety symptoms and personality disorder are found to be associated with nonremission in TRD.
Study details
Compounds studied
Ketamine
Topics studied
Depression
Treatment-Resistant Depression
Study characteristics
Placebo-Controlled
Double-Blind
Participants
61
Humans
Compound Details
The psychedelics given at which dose and how many times
Ketamine 0.25 - 0.5mg | 1x